Sanofi and Regeneron are studying the long-term effect of dupilumab on the prevention of lung function decline in adult patients with uncontrolled moderate to severe asthma. This phase 3b/4 study (ATLAS) is an interventional, randomized, parallel group, treatment, double-blind, two-arm study to assess the effect of dupilumab compared with standard-of-care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma.
The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double-blinded treatment period. There will be a post-treatment follow-up period up to 12 weeks.
A number of clinical trial sites are available and recruiting patients across the United States. For additional information, or to learn if you might be eligible, please visit Sanofi Studies or ClinicalTrials.gov.